A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN-001, a HumanizedMonoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) andSubjects with Thyroid Eye Disease (TED)

Project: Research project

Project Details

Description

A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects with Thyroid Eye Disease (TED)
StatusActive
Effective start/end date2/25/22 → 2/25/27

Funding

  • VIRIDIAN THERAPEUTICS, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint